系统性硬化症中数字的全身药理治疗:系统性文献综述
Laura Ross1, Nancy Maltez2, Michael Hughes3,4
1Department of Medicine and Rheumatology, University of Melbourne at St Vincent's Hospital, Melbourne, Victoria, Australia.
Rheumatology (Oxford, England)
|June 19, 2023
概括
系统性药理疗法如伊洛普罗斯特,PDE5抑制剂和阿托瓦斯塔丁在系统性硬化症 (SSc) 数字 (DUs) 中显示出有效性. 然而,需要更强大的数据来建立SSc DU的最佳治疗指南.
科学领域:
- 类风湿病学 类风湿病学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性硬化症 (SSc) 和数字 (DUs) 是一种常见且令人衰弱的并发症.
- 对SSc DU的有效管理策略对于改善患者的治疗结果至关重要.
- 目前缺乏基于证据的指导方针,用于SSc DU的药理治疗.
研究的目的:
- 系统地审查和评估针对SSc数字的全身药理疗法的证据.
- 为制定SSc DU的基于证据的治疗指南提供信息.
主要方法:
- 对七个数据库进行了系统的文献审查.
- 包括SSc DU的成年患者的随机对照试验 (RCT) 和前性纵向观察研究 (OBS).
- 进行了数据提取和偏差风险评估,由于研究异质性,使用了叙事总结.
主要成果:
- 分析了47项涉及2588名患者的研究.
- 静脉注射伊洛普罗斯特,固酶-5抑制剂和阿托瓦斯塔丁在治疗活跃的SSc DUs方面表现出有效性.
- 博森坦显示了未来的DU率的降低,Janus激酶抑制剂可能对活跃的DU有效,尽管证据质量有所不同.
结论:
- 通过四种药物类别的几种全身治疗,可以有效地管理SSc DUs.
- 由于缺乏可靠的数据,目前无法确定最佳治疗方案.
- 由于SSc DU管理的可用证据质量相对较低,因此需要进一步研究.
相关概念视频
Peptic Ulcer Disease IV: Management
115
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
115
Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
575
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
575
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202


